drugset / Trial / NCT04928950
Charcoal in Lung Cancer Patients Undergoing TEMLA
NaSingle-groupOpen-labelSupportive care
Summary
This proof-of-concept study serves as the preliminary step to prove safety of oral activated charcoal (OAC) in patients with solid tumors before moving to a hematologic malignancy patient population.
Timeline
- Start
- 2022-01-26
- Primary completion
- 2025-01
- Completion
- 2025-01
Outcome
Outcome not reported
Stopped: “Because of logistic challenges and lack of product among other factors, we decided to completely withdrawn this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Activated Charcoal | Other / unclassified | — | Oral |